Association of dysglycaemia with persistent infarct core iron in patients with acute ST-segment elevation myocardial infarction

被引:1
|
作者
Lechner, Ivan [1 ]
Reindl, Martin [1 ]
Oberhollenzer, Fritz [1 ]
Tiller, Christina [1 ]
Holzknecht, Magdalena [1 ]
Fink, Priscilla [1 ]
Kremser, Thomas [1 ]
Bonatti, Paolo [1 ]
Troger, Felix [2 ]
Henninger, Benjamin [2 ]
Mayr, Agnes [2 ]
Bauer, Axel [1 ]
Metzler, Bernhard [1 ]
Reinstadler, Sebastian J. [1 ]
机构
[1] Med Univ Innsbruck, Univ Clin Internal Med Cardiol & Angiol 3, Anichstrasse 35, A-6020 Innsbruck, Austria
[2] Med Univ Innsbruck, Univ Clin Radiol, Anichstr 35, A-6020 Innsbruck, Austria
基金
奥地利科学基金会;
关键词
ST-elevation myocardial infarction; HbA1c; Intramyocardial hemorrhage; Persistent iron; Iron resolution Cardiac magnetic resonance imaging; ISCHEMIA/REPERFUSION INJURY; INFUSION; TRIAL;
D O I
10.1016/j.jocmr.2024.100996
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Dysglycaemia increases the risk of myocardial infarction and subsequent recurrent cardiovascular events. However, the role of dysglycaemia in ischemia/reperfusion injury with development of irreversible myocardial tissue alterations remains poorly understood. In this study we aimed to investigate the association of ongoing dysglycaemia with persistence of infarct core iron and their longitudinal changes over time in patients undergoing primary percutaneous coronary intervention (PCI) for acute ST -segment elevation myocardial infarction (STEMI). Methods: We analyzed 348 STEMI patients treated with primary PCI between 2016 and 2021 that were included in the prospective MARINA-STEMI study (NCT04113356). Peripheral venous blood samples for glucose and glycated hemoglobin (HbA1c) measurements were drawn on admission and 4 months after STEMI. Cardiac magnetic resonance (CMR) imaging including T2 * mapping for infarct core iron assessment was performed at both time points. Associations of dysglycaemia with persistent infarct core iron and iron resolution at 4 months were calculated using multivariable regression analysis. Results: Intramyocardial hemorrhage was observed in 147 (42%) patients at baseline. Of these, 89 (61%) had persistent infarct core iron 4 months after infarction with increasing rates across HbA1c levels (< 5.7%: 33%, >= 5.7: 79%). Persistent infarct core iron was independently associated with ongoing dysglycaemia defined by HbA1c at 4 months (OR: 7.87 [95% CI: 2.60-23.78]; p < 0.001), after adjustment for patient characteristics and CMR parameters. The independent association was present even after exclusion of patients with diabetes (pre- and newly diagnosed, n = 16). Conclusions: In STEMI patients treated with primary PCI, ongoing dysglycaemia defined by HbA1c is independently associated with persistent infarct core iron and a lower likelihood of iron resolution. These findings suggest a potential association between ongoing dysglycaemia and persistent infarct core iron, which warrants further investigation for therapeutic implications.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] ST-segment elevation myocardial infarction
    Yerem Yeghiazarians
    Peter H. Stone
    Current Treatment Options in Cardiovascular Medicine, 2002, 4 (1) : 3 - 23
  • [32] ST-segment elevation myocardial infarction
    Birgit Vogel
    Bimmer E. Claessen
    Suzanne V. Arnold
    Danny Chan
    David J. Cohen
    Evangelos Giannitsis
    C. Michael Gibson
    Shinya Goto
    Hugo A. Katus
    Mathieu Kerneis
    Takeshi Kimura
    Vijay Kunadian
    Duane S. Pinto
    Hiroki Shiomi
    John A. Spertus
    P. Gabriel Steg
    Roxana Mehran
    Nature Reviews Disease Primers, 5
  • [33] Fondaparinux in patients with ST-segment elevation myocardial infarction
    Hartig, Frank
    Eller, Philipp
    Pechlaner, Christoph
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (17): : 2087 - 2087
  • [34] ST-segment elevation myocardial infarction
    Vogel, Birgit
    Claessen, Bimmer E.
    Arnold, Suzanne, V
    Chan, Danny
    Cohen, David J.
    Giannitsis, Evangelos
    Gibson, C. Michael
    Coto, Shinya
    Katus, Hugo A.
    Kerneis, Mathieu
    Kimura, Takeshi
    Kunadian, Vijay
    Pinto, Duane S.
    Shiomi, Hiroki
    Spertus, John A.
    Steg, P. Gabriel
    Mehran, Roxana
    NATURE REVIEWS DISEASE PRIMERS, 2019, 5 (1)
  • [35] ST-Segment Elevation Myocardial Infarction
    Younis, George A.
    TEXAS HEART INSTITUTE JOURNAL, 2022, 49 (05) : 111 - 111
  • [37] Bivalirudin in patients with ST-segment elevation myocardial infarction
    Coughlan, J. J.
    Kastrati, Adnan
    LANCET, 2022, 400 (10366): : 1822 - 1823
  • [38] Impact of plaque rupture on infarct size in ST-segment elevation anterior acute myocardial infarction
    Kusama, Ikuyoshi
    Hibi, Kiyoshi
    Kosuge, Masami
    Nozawa, Naoki
    Ozaki, Hiroyuki
    Yano, Hideto
    Sumita, Shinnichi
    Tsukahara, Kengo
    Okuda, Jun
    Ebina, Toshiaki
    Umemura, Satoshi
    Kimura, Kazuo
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (13) : 1230 - 1237
  • [39] BivalirudinIn Patients with ST-Segment Elevation Myocardial Infarction
    Monique P. Curran
    Drugs, 2010, 70 : 909 - 918
  • [40] Bivalirudin In Patients with ST-Segment Elevation Myocardial Infarction
    Curran, Monique P.
    DRUGS, 2010, 70 (07) : 909 - 918